CAR-T cells take on stubborn leukemia after transplant in new trial
NCT ID NCT07441291
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for patients with B-cell acute lymphoblastic leukemia who still have small amounts of cancer cells (minimal residual disease) after a stem cell transplant. One group receives a single infusion of their own genetically modified immune cells (CAR-T therapy), while the other gets standard chemotherapy plus donor immune cells. The goal is to see which approach better clears these leftover cancer cells and prevents relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19 CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could offer a more effective way to eliminate lingering leukemia cells after a stem cell transplant, potentially reducing relapse risk.
- What could go wrong
- This is a relatively small, early-phase trial, and CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological problems. It may not prove superior to standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENETIC HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental cell therapy takes on tough leukemia
- New immune cell therapy targets Hard-to-Treat leukemia in early trial
- Engineered immune cells take aim at tough blood cancers
- New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers
- Experimental CAR-T therapy shows promise in small leukemia trial
- New gene therapy injection shows promise for tough leukemia